[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366541-105":59,"doc-detail-366541-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","emerging-her2-targeting-immunotherapy-for-cholangiocarcinoma-review-research","Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma - Review - Research","","Cholangiocarcinoma (CCA) is a fatal bile duct malignancy marked by intrinsic resistance to standard chemotherapy, weak therapeutic responses, frequent recurrence, and poor overall prognosis, with limited effective treatment options. This review explains the oncogenic role of HER2 and evaluates why HER2—successful as a target in breast and gastric cancers—has not been fully established in CCA. It highlights HER2 alterations linked to poorer outcomes in liver fluke-associated CCA clusters and summarizes emerging HER2-targeted immunotherapeutic strategies, emphasizing the importance of animal models to translate preclinical evidence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/emerging-her2-targeting-immunotherapy-for-cholangiocarcinoma-review-research/366541/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/emerging-her2-targeting-immunotherapy-for-cholangiocarcinoma-review-research/366541.png","ImageObject",300,407,{"name":92,"@type":93},"Elsa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is cholangiocarcinoma (CCA) difficult to treat with standard chemotherapy?","Question",{"text":112,"@type":113},"CCA is intrinsically resistant to standard chemotherapy and shows poor response rates. The disease also commonly recurs and develops resistant phenotypes to first-line therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does HER2 play in cancers, and why is it relevant to CCA?",{"text":117,"@type":113},"HER2 promotes proliferation, differentiation, and survival through multiple signaling pathways. The review discusses HER2 as a potentially promising immunotherapy target in CCA despite limited success compared with breast and gastric cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"How are HER2 alterations connected to prognosis in liver fluke-associated CCA?",{"text":121,"@type":113},"The review reports that HER2 alterations have been identified as part of a signature associated with poorer prognosis in liver fluke-associated CCA clusters.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366541,1790308738,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Tech Science Press  \nDoi:10.32604/or.2025.065319  \nREVIEW  \nEmerging HER2 Targeting Immunotherapy for Cholangiocarcinoma  \nPrin Sungwan1, Jutatip Panaampon1,2, Ratchaneewan Sumankan1,3, Genki Aoki1 and Seiji Okada1, *  \n1 Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate School of Medical Sciences, Kumamoto University 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan  \n2 Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450Brookline Avenue, Boston, MA02215, USA  \n3 Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai, 50200, Thailand  \n*Corresponding Author: [Seiji Okada. Email: okadas@kumamoto-u.ac.jp](Seiji Okada. Email: okadas@kumamoto-u.ac.jp)[ ](Seiji Okada. Email: okadas@kumamoto-u.ac.jp)[Received: 10 March 2025](Received: 10 March 2025); [Accepted: 11 June 2025](Accepted: 11 June 2025); [Published: 28 August 2025](Published: 28 August 2025)  \nABSTRACT: Cholangiocarcinoma (CCA) is a fatal bile duct malignancy. CCA is intrinsically resistant to standard chemotherapy, responds poorly to it, and has a poor prognosis. Effective treatments for cholangiocarcinoma remain elusive, and a breakthrough in CCA treatment is still awaited. The human epidermal growth factor receptor 2 (HER2) plays an oncogenic role by promoting an aggressive cancer phenotype through multiple pathways. While HER2 has shown increasing potential as an effective target for breast and gastric cancers over the last decade, this has not been the case for CCA. This review explores the possibility of targeting HER2 in CCA immunotherapy. Key findings suggest that HER2 alterations have been reported as one of the signatures associated with a poorer prognosis in liver fluke-associated CCA, the most prevalent subtype in Southeast Asia. Furthermore, we assess recent advances in HER2-targeted therapeutic approaches, presenting the current stage, rationale, and evidence supporting the use of HER2 as a promising therapeutic target for cancer immunotherapy in CCA. We also emphasize the crucial role of animal models in developing anticancer therapies. In summary, focusing on HER2 expression could provide alternative strategies for the HER2-altered CCA cluster.  \nKEYWORDS: Cholangiocarcinoma; human epidermal growth factor receptor 2 (HER2); immunotherapy; animal models for cancer study  \n1 Introduction  \nCholangiocarcinoma (CCA) is a deadly and aggressive bile duct malignancy [1–3] . Most CCA patients have a poor prognosis with very low 5-year survival rates, and the median survival rate is less than 1 year [4–6]. Moreover, the response rate to standard chemo-drugs is less than 40%. Tumor recurrence and resistant phenotype to first-line therapy often occur [7–9] . There are still no effective treatment regimens or strategies for CCA. Only R0 surgical resection (completely removed, with no microscopic or macroscopic residual tumor at the surgical margins) [10–12] is considered the best strategy for CCA treatment, whilst only a few patients can be operated on with the resection due to a lack of signs/symptoms [10] . The human epidermal growth factor receptor 2 (HER2) is a member of the human epidermal growth factor receptor (HER) family, which plays oncogenic roles in several malignancies. HER2 promotes cancer cell proliferation, differentiation, and survival via multiple signal transduction pathways [13,14] . In the last decade, there has been increasing potential for using HER2 as an effective target for breast and gastric cancers but not in CCA. Recently, the exploration of CCA cancer biology revealed that HER2 alterations have been  \nCopyright © 2025 The Authors. Published by Tech Science Press.  \nThis work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \ndominantly observed in liver fluk","cbCaia7I6RnBJDhv","https://ap.wps.com/l/cbCaia7I6RnBJDhv","pdf",7260709,29,"English","# Abstract\n# Introduction\n# The Current Status of CCA\n# Emerging HER2-Targeted Immunotherapy (Overview)","[{\"question\":\"Why is cholangiocarcinoma (CCA) difficult to treat with standard chemotherapy?\",\"answer\":\"CCA is intrinsically resistant to standard chemotherapy and shows poor response rates. The disease also commonly recurs and develops resistant phenotypes to first-line therapy.\"},{\"question\":\"What role does HER2 play in cancers, and why is it relevant to CCA?\",\"answer\":\"HER2 promotes proliferation, differentiation, and survival through multiple signaling pathways. The review discusses HER2 as a potentially promising immunotherapy target in CCA despite limited success compared with breast and gastric cancers.\"},{\"question\":\"How are HER2 alterations connected to prognosis in liver fluke-associated CCA?\",\"answer\":\"The review reports that HER2 alterations have been identified as part of a signature associated with poorer prognosis in liver fluke-associated CCA clusters.\"}]","Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma - Review - Research | PDF",1790166031,73,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c0e24654cca709b6c31cfc6584dad8b.webp",983,1271,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee1305efdd80ed4d34beae779c0f9877.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4e7125a04028bc7f07f0e0150f67513.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9bc4cca674ef40d2fe6d2d239694d9a.webp",980,1267]